Serological markers in psoriatic arthritis: Promising tools

Experimental Biology and Medicine

Volumn 238, Issue 12, 2013, Pages 1431-1436

  Ramonda, Roberta ^a   Modesti, Valentina ^a   Ortolan, Augusta ^a   Scanu, Anna ^a   Bassi, Nicola ^a   Oliviero, Francesca ^a   Punzi, Leonardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

biological markers; inflammation; metalloproteinase 3; Psoriatic arthritis; tumor necrosis factor alpha; vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; PENTRAXIN 3; STROMELYSIN; VASCULOTROPIN;

ADULT; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESES SCORE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; SEROLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VISUAL ANALOGUE SCALE FOR GLOBAL ASSESSMENT;

BIOLOGICAL MARKERS; INFLAMMATION; METALLOPROTEINASE-3; PSORIATIC ARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PAIN MEASUREMENT; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888403171     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213506435     Document Type: Article

References (43)

1. Gladman DD.Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint disease?.Ann Rheum Dis. 2006;65:22-4.
2. Haglund E,Bremander AB,Petersson IF,Strömbeck B,Bergman S,Jacobsson LT,Turkiewicz A,Geborek P,Englund M.Prevalence of spondyloarthritis and its subtypes in southern Sweden.Ann Rheum Dis. 2011;70:943-8.
3. Punzi L,Ramonda R.Psoriatic arthritis. When the heterogeneity requires normality.Reumatismo. 2012;64:59-65.
4. Gladman DD,Shuckett R,Russell ML,Thorne JC,Schachter RK.Psoriatic arthritis (PSA)-an analysis of 220 patients.Q J Med. 1987;62:127-41.
5. Gladman DD.Future trends in research in psoriatic arthritis.J Rheumatol Suppl. 2012;89:106-10.
6. Fitzgerald O,Chandran V.Update on Biomarkers in psoriatic arthritis: a report from the GRAPPA 2010 Annual Meeting.J Rheumatol. 2012;39:427-30.
7. Chandran V,Cook RJ,Edwin J,Shen H,Pellett FJ,Shanmugarajah S,Rosen CF,Gladman DD.Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis.Rheumatology. 2010;49:1399-405.
8. Strober B,Teller C,Yamauchi P,Miller JL,Hooper M,Yang YC,Dann F.Effects on etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.Br J Dermatol. 2008;159:322-30.
9. Cañete JD,Pablos JL,Sanmartí R,Mallofré C,Marsal S,Maymó J,Gratacós J,Mezquita J,Mezquita C,Cid MC.Antiangiogenetic effects of anti-tumor necrosis factor-α therapy with infliximab in psoriatic arthritis.Arthritis Rheum. 2004;50:1636-41.
10. Pedersen SJ,Hetland ML,Sørensen IJ,Ostergaard M,Nielsen HJ,Johansen JS.Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors.Clin Rheumatol. 2010;29:1301-9.
11. Breviario F,d'Aniello EM,Golay J,Peri G,Bottazzi B,Bairoch A,Saccone S,Marzella R,Predazzi V,Rocchi M.Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component.J Biol Chem. 1992;267:22190-7.
12. Bevelacqua V,Libra M,Mazzarino MC,Gangemi P,Nicotra G,Curatolo S,Massimino D,Plumari A,Merito P,Valente G,Stivala F,La Greca S,Malaponte G.Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.Int J Mol Med. 2006;18:415-23.
13. Taylor W,Gladman D,Helliwell P,Marchesoni A,Mease P,Mielants H.Classification criteria for psoriatic arthritis: development of new criteria from a large international study.Arthritis Rheum. 2006;54:2665-7314.
14. Mease PJ,Antoni CE,Gladman DD,Taylor WJ.Psoriatic arthritis assessment tools in clinical trials.Ann Rheum Dis. 2005;64:ii49-54.
15. Mease PJ.Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI).Arthritis Care Res (Hoboken). 2011;63:S64-85.
16. Fitzgerald O,Chandran V.Update on Biomarkers in Psoriatic Arthritis: A Report from the GRAPPA 2010 Annual Meeting.J Rheumatol. 2012;39:427-30.
17. Modesti V,Ramonda R,Ortolan A,Lorenzin M,Lo Nigro A,Frallonardo P,Oliviero F,Campana C,Punzi L.Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study.Scand J Rheumatol. 2012;41:90-1.
18. Labarrere CA,Lee JB,Nelson DR,Al-Hassani M,Miller SJ,Pitts DE.C-reactive protein, arterial endothelial activation, and the development of transplant coronary artery disease: a prospective study.Lancet. 2002;360:1462-7.
19. Manicourt DH,Fujimoto N,Obata K,Thonar EJ.Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation.Arthritis Rheum. 1995;38:1031-9.
20. van Kuijk AW,DeGroot J,Koeman RC,Sakkee N,Baeten DL,Gerlag DM,Tak PP.Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo.PLoS One. 2010;5:e12556-e12556.
21. Kane D,Gogarty M,O'leary J,Silva I,Bermingham N,Bresnihan B,Fitzgerald O.Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate.Arthritis Rheum. 2004;50:3286-95.
22. Wagner CL,Visvanathan S,Elashoff M,McInnes IB,Mease PJ,Krueger GG, et al.Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab.Ann Rheum Dis. 2013;72:83-8.
23. Chimenti MS,Perricone C,Graceffa D,Di Muzio G,Ballanti E,Guarino MD,Conigliaro P,Greco E,Kroegler B,Perricone R.Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment.Clin Exp Rheumatol. 2012;30:23-30.
24. Ribbens C,Martin y Porras M,Kaiser MJ,Jaspar JM,Damas P,Houssiau FA,Malaise MG.Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.Ann Rheum Dis. 2002;61:161-6.
25. Xia L,Shen H,Xiao W,Lu J.Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels.Cytokine. 2011;53:289-91.
26. Mastroianni A,Minutilli E,Mussi A,Bordignon V,Trento E,D'Agosto G,Cordiali-Fei P,Berardesca E.Cytokine profiles during infliximab monotherapy in psoriatic arthritis.Br J Dermatol. 2005;153:531-6.
27. Punzi L,Podswiadek M,Oliviero F,Lonigro A,Modesti V,Ramonda R,Tosesco S.Laboratory findings in psoriatic arthritis.Reumatismo. 2007;59:52-5.
28. Drouart M,Saas P,Billot M,Cedoz JP,Tiberghien P,Wendling D,Toussirot E.High serum vascular endothelial growth factor correlates with disease activity of spondyloarthropathies.Clin Exp Immunol. 2003;132:158-62.
29. Fearon U,Griosios K,Fraser A,Reece R,Emery P,Jones PF,Veale DJ.Angiopoietins, growth factors, and vascular morphology in early arthritis.J Rheumato. 2003;30:260-8.
30. Fink AM,Cauza E,Hassfeld W,Dunky A,Bayer PM,Jurecka W,Steiner A.Vascular endothelial growth factor in patients with psoriatic arthritis.Clin Exp Rheumatol. 2007;25:305-8.
31. Ballara S,Taylor PC,Reusch P,Marmé D,Feldmann M,Maini RN,Paleolog EM.Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis.Arthritis Rheum. 2001;44:2055-64.
32. Rolph MS,Zimmer S,Bottazzi B,Garlanda C,Mantovani A,Hansson GK.Production of the long pentraxin PTX3 in advanced atherosclerotic plaques.Arterioscler Thromb Vasc Biol. 2002;22:e10-4.
33. Inoue K,Sugiyama A,Reid PC,Ito Y,Miyauchi K,Mukai S,Miyamoto K,Satoh H,Kohno I,Kurata T,Ota H,Mantovani A,Hamakubo T,Daida H,Kodama T.Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris.Arterioscler Thromb Vasc Biol. 2007;27:161-7.
34. Latini R,Maggioni AP,Peri G,Gonzini L,Lucci D,Mocarelli P,Vago L,Pasqualini F,Signorini S,Soldateschi D,Tarli L,Schweiger C,Fresco C,Cecere R,Tognoni G,Mantovani A.Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.Circulation. 2004;110:2349-54.
35. Ramonda R,Lo Nigro A,Modesti V,Nalotto L,Musacchio E,Iaccarino L,Punzi L,Doria A.Atherosclerosis in psoriatic arthritis.Autoimmun Rev. 2011;10:773-8.
36. Tam LS,Shang Q,Li EK,Tomlinson B,Chu TT,Li M,Leung YY,Kwok LW,Wong KC,Li TK,Yu T,Zhu TY,Kun EW,Yip GW,Yu CM.Subclinical carotid atherosclerosis in patients with psoriatic arthritis.Arthritis Rheum. 2008;59:1322-31.
37. Contessa C,Ramonda R,Lo Nigro A,Modesti V,Lorenzin M,Puato M,Zanon M,Balbi G,Doria A,Punzi L.Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data.Reumatismo. 2009;61:298-305.
38. Sterry W,Strober BE,Menter A.Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review.Br J Dermatol. 2007;157:649-55.
39. Sidiropoulos PI,Siakka P,Pagonidis K,Raptopoulou A,Kritikos H,Tsetis D,Boumpas DT.Sustained improvement of vascular endothelial function during anti-TNF alpha treatment in rheumatoid arthritis patients.Scand J Rheumatol. 2009;38:6-10.
40. Del Porto F,Laganà B,Lai S,Nofroni I,Tinti F,Vitale M,Podestà E,Mitterhofer AP,D'Amelio R.Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis.Rheumatology. 2007;46:1111-5.
41. Turiel M,Tomasoni L,Sitia S,Cicala S,Gianturco L,Ricci, Atzeni F,De Gennaro Colonna V,Longhi M,Sarzi-Puttini P.Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis.Cardiovasc Ther. 2010;28:e53-64.
42. Gonzalez-Juanatey C,Testa A,Garcia-Castelo A,Garcia-Porrua C,Llorca J,Gonzalez-Gay MA.Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.Arthritis Rheum. 2004;51:447-50.
43. Eder L,Jayakar J,Shanmugarajah S,Thavaneswaran A,Pereira D,Chandran V,Rosen CF,Gladman DD.The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone.Ann Rheum Dis. 2013;72:715-20.